» Articles » PMID: 39281978

A Predictive Machine-learning Model for Clinical Decision-making in Washed Microbiota Transplantation on Ulcerative Colitis

Overview
Specialty Biotechnology
Date 2024 Sep 16
PMID 39281978
Authors
Affiliations
Soon will be listed here.
Abstract

Machine learning based on clinical data and treatment protocols for better clinical decision-making is a current research hotspot. This study aimed to build a machine learning model on washed microbiota transplantation (WMT) for ulcerative colitis (UC), providing patients and clinicians with a new evaluation system to optimize clinical decision-making. Patients with UC who underwent WMT via mid-gut or colonic delivery route at an affiliated hospital of Nanjing Medical University from April 2013 to June 2022 were recruited. Model ensembles based on the clinical indicators were constructed by machine-learning to predict the clinical response of WMT after one month. A total of 366 patients were enrolled in this study, with 210 patients allocated for training and internal validation, and 156 patients for external validation. The low level of indirect bilirubin, activated antithrombin III, defecation frequency and cholinesterase and the elderly and high level of creatine kinase, HCO and thrombin time were related to the clinical response of WMT at one month. Besides, the voting ensembles exhibited an area under curve (AUC) of 0.769 ± 0.019 [accuracy, 0.754; F1-score, 0.845] in the internal validation; the AUC of the external validation was 0.614 ± 0.017 [accuracy, 0.801; F1-score, 0.887]. Additionally, the model was available at https://wmtpredict.streamlit.app. This study pioneered the development of a machine learning model to predict the one-month clinical response of WMT on UC. The findings demonstrate the potential value of machine learning applications in the field of WMT, opening new avenues for personalized treatment strategies in gastrointestinal disorders. clinical trials, NCT01790061. Registered 09 February 2013 - Retrospectively registered, https://clinicaltrials.gov/study/NCT01790061.

References
1.
Zhang F, Lu G, Wang X, Wu L, Li R, Nie Y . Concept, breakthrough, and future of colonic transendoscopic enteral tubing. Chin Med J (Engl). 2024; 137(6):633-635. PMC: 10950190. DOI: 10.1097/CM9.0000000000003020. View

2.
Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J . Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770. PMC: 6487890. DOI: 10.1016/S0140-6736(16)32126-2. View

3.
Shi H, Feng Y, Jiang J, Zhao J, Li X, Liu X . Correlations between the serum bilirubin level and ulcerative colitis: a case-control study. Eur J Gastroenterol Hepatol. 2019; 31(8):992-997. DOI: 10.1097/MEG.0000000000001466. View

4.
Wang Y, Zhang S, Borody T, Zhang F . Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases. Chin Med J (Engl). 2022; 135(16):1927-1939. PMC: 9746749. DOI: 10.1097/CM9.0000000000002339. View

5.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y . AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022; 7(7):648-657. DOI: 10.1016/S2468-1253(22)00022-X. View